主要进行核素影像和新型医用诊疗材料的研究，研究重点是：1. 基于多肽和纳米抗体的新型核素诊断试剂的研发，2. 基于金属-功能分子配位的生物医学材料在肿瘤诊疗中的应用。以新型核素分子标记方法的开发以及新型肿瘤靶向分子的使用，解决临床肿瘤中诊断精准度的问题，探索核素诊断试剂与肿瘤亚细胞群相互作用的机制以及药代动力学行为，发展精准靶向肿瘤诊疗技术。

教育及工作经历：

2002-2008 南京大学生命科学学院博士（生物化学与分子生物学）

2008-2013 美国威斯康星大学放射学系助理研究员

2013-2014 美国威斯康星大学放射学系助理科学家

2014-2019 美国密歇根大学放射学系助理教授

2019-至今  南京大学医学院教授、博导

核医学与分子诊断

青年海外高层次人才计划，基于纳米抗体的新型分子影像试剂的研究

国奖自然基金面上项目，新型靶向PSMA的前列腺肿瘤核素诊疗试剂的研究

获奖情况：

2012年、2016年，美国核医学与分子影像学会Berson-Yalow奖

2014年，美核医学与分子影像学会青年研究学者奖（Young Scientist Award）一等奖

2015年，Elsa U. Pardee Foundation Award

2019年，中组部“青年千人”计划

2020年，江苏省“双创人才”计划

1. Yang D, Comeau A, Bowen W, Mach R, Ross B, Hong H, Van Dort M. Design and investigation of a [18F]-labeled benzamide derivative as a high affinity dual sigma receptor subtype radioligand for prostate tumor imaging. Mol Pharm, 14, 770-780, 2017.

2. Chen D, Yang D, Dougherty C, Lu W, Wu H, He X, Cai T, Van Dort M, Ross B, Hong H. In vivo targeting and PET imaging of tumor with intrinsically radioactive metal-organic frameworks (MOF) nanomaterials. ACS Nano, 11, 4315-4327, 2017.

3. Peng Y, Yang D, Lu W, Hu X, Hong H, Cai T. Positron emission tomography (PET) guided glioblastoma targeting by a fullerene-based nanoplatform with fast renal clearance. Acta Biomater, 61, 193-203, 2017.

4. Chen D, Zhang G, Li R, Guan M, Wang X, Zou T, Zhang Y, Wang C, Shu C, Hong H, Wan LJ. Biodegradable, Hydrogen Peroxide, and Glutathione Dual Responsive Nanoparticles for Potential Programmable Paclitaxel Release. J Am Chem Soc. 2018 Jun 20;140(24):7373-7376.

5. Yang D, Yao X, Dong J, Wang N, Du Y, Sun S, Gao L, Zhong Y, Qian C, Hong H. Design and Investigation of Core/Shell GQDs/hMSN Nanoparticles as an Enhanced Drug Delivery Platform in Triple-Negative Breast Cancer. Bioconjug Chem. 2018;29(8):2776-2785.

6. Chen D, Zhou Y, Yang D, Guan M, Zhen M, Lu W, Van Dort ME, Ross BD, Wang C, Shu C, Hong H. Positron Emission Tomography/Magnetic Resonance Imaging of Glioblastoma Using a Functionalized Gadofullerene Nanoparticle. ACS Appl Mater Interfaces. 2019;11:21343-21352.

7. Xu C, Nam J, Hong H, Xu Y, Moon JJ. Positron Emission Tomography-Guided Photodynamic Therapy with Biodegradable Mesoporous Silica Nanoparticles for Personalized Cancer Immunotherapy. ACS Nano. 13(10):12148-12161, 2019.

8. Peng Y, Ye C, Yan R, Lei Y, Ye D, Hong H, Cai T. Activatable Core-Shell Metallofullerene: An Efficient Nanoplatform for Bimodal Sensing of Glutathione. ACS Appl Mater Interfaces. 2019 Dec 18;11(50):46637-46644.

9. Xu C, Hong H, Lee Y, Park KS, Sun M, Wang T, Aikins ME, Xu Y, Moon JJ. Efficient Lymph Node-Targeted Delivery of Personalized Cancer Vaccines with Reactive Oxygen Species-Inducing Reduced Graphene Oxide Nanosheets. ACS Nano. 2020 Oct 27;14(10):13268-13278.

10. Zheng Z, Chen Y, Hong H, Shen Y, Wang Y, Sun J, Wang X. The "Yin and Yang" of Immunomodulatory Magnesium-Enriched Graphene Oxide Nanoscrolls Decorated Biomimetic Scaffolds in Promoting Bone Regeneration. Adv Healthc Mater. 2021 Jan;10(2):e2000631.

11. Lu W, Cong Y, Yang D, Chen D, Yang G, Wang Y, Van Dort ME, Ross BD, Mazar AP, Chu BB, Hong H. Engineered Antibody Fragment against the Urokinase Plasminogen Activator for Fast Delineation of Triple-Negative Breast Cancer by Positron Emission Tomography. Mol Pharm. 2021 Apr 5;18(4):1690-1698.

12. Zhao B, Dong Z, Liu W, Lou F, Wang Q, Hong H, Wang Y. Co-administration of combretastatin A4 nanoparticles and anti-PD-L1 for synergistic therapy of hepatocellular carcinoma. J Nanobiotechnology. 2021 May 1;19(1):124.

13. Zeng Y, Xiao J, Cong Y, Liu J, He Y, Ross BD, Xu H, Yin Y, Hong H, Xu W. PEGylated Nanoscale Metal-Organic Frameworks for Targeted Cancer Imaging and Drug Delivery. Bioconjug Chem. 2021 Oct 20;32(10):2195-2204.

14. Zhong Y, Zhang L, Sun S, Zhou Z, Ma Y, Hong H, Yang D. Sequential drug delivery by injectable macroporous hydrogels for combined photodynamic-chemotherapy. J Nanobiotechnology. 2021 Oct 23;19(1):333.

15. Peng Y, Cong Y, Lei Y, Sun F, Xu M, Zhang J, Fang L, Hong H, Cai T. Transforming Passive into Active: Multimodal Pheophytin-Based Carbon Dots Customize Protein Corona to Target Metastatic Breast Cancer. Adv Healthc Mater. 2022 Jan 15:e2102270.